SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:lup.lub.lu.se:3e39c7be-2963-417b-8fc3-24eabfa6cc99"
 

Search: id:"swepub:oai:lup.lub.lu.se:3e39c7be-2963-417b-8fc3-24eabfa6cc99" > Effects and serum l...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Jönsson, A. (author)

Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes

  • Article/chapterEnglish2001

Publisher, publication year, extent ...

  • 2001-12-20
  • Wiley,2001

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:3e39c7be-2963-417b-8fc3-24eabfa6cc99
  • https://lup.lub.lu.se/record/1118542URI
  • https://doi.org/10.1046/j.1463-1326.2001.00152.xDOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objective: To study the effects and serum levels of glibenclamide (Gb) and its active metabolites in patients on chronic Gb medication on different daily doses. Material and methods: Fifty patients with type 2 diabetes on regular Gb therapy (1.75-14.0 mg daily). Blood samples were taken immediately before and 90 min after regular Gb intake. A standardized breakfast was served 30 min after drug intake. Serum insulin and proinsulin levels were determined by ELISA methods without cross-reactivities. Serum drug levels were determined by HPLC. Fischer's Rto Z-test (correlation coefficients) and paired Student t-tests were used when comparing values within the entire group and unpaired non-parametric Mann-Whitney tests were used when comparing high and low dose levels. A p-value <0.05 was considered significant. Results: There were significant correlations between daily Gb dose, on the one hand, and, on the other, HbAl(c) (r=0.55), -insulin (r=-0.59) and Delta -proinsulin (r=-0.52) levels. Significant correlations between Gb therapy duration and insulin (r=-0.40) and proinsulin (r=-0.34) secretion and between Gb dose and ratio proinsulin/insulin (RPI) at both time points (r=0.32 and 0.30) were also found. The RPI was lower after Gb intake. In patients on greater than or equal to 10.5 mg steady state serum metabolite levels (Ml and Ml + M2) were higher (29(0-120) and 33 (0-120) ng/ml) than those of Gb itself (18(0-64) ng/ml). A great inter-subject variability in Gb levels at both time points was seen. Conclusions: Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. The effect was more pronounced in patients on a low Gb dose, either because of less impaired beta -cells in those receiving low doses, or due to reduced sulphonylurea sensitivity in those on high dosage (down-regulation). In patients on a daily dose of 10.5 mg or more, serum metabolite levels of clinical relevance were demonstrated; the metabolites may contribute to hypoglycaemic events.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hallengren, BengtLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)endo-bha (author)
  • Rydberg, T. (author)
  • Melander, A. (author)
  • Institutionen för kliniska vetenskaper, MalmöMedicinska fakulteten (creator_code:org_t)

Related titles

  • In:Diabetes, Obesity and Metabolism: Wiley3:6, s. 403-4091462-8902

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Jönsson, A.
Hallengren, Beng ...
Rydberg, T.
Melander, A.
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Endocrinology an ...
Articles in the publication
Diabetes, Obesit ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view